Table 4.
Percent least-squares mean changes from baseline to week 14 in neurohormone levels
| Variable | Mean (SD) |
LSM Change (SEM) | Ratio (SEM)a | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| Baseline | Endpoint | |||||
| BNP, pg/mL | ||||||
| Valsartan | 93.2 (80.2) (n = 60) | 94.0 (78.6) (n = 61) | 97.5 (110.8) (n = 60) | |||
| Placebo | 120.3 (119.5) (n = 73) | 109.9 (105.0) (n = 74) | 93.9 (109.9) (n = 73) | 103.9 (114.1) | 80.0, 134.9 | 0.774 |
| Noradrenaline, pg/mL | ||||||
| Valsartan (n = 54) | 529.1 (258.9) | 538.5 (282.6) | 94.8 (106.9) | |||
| Placebo (n = 64) | 621.1 (303.9) | 589.1 (254.2) | 100.4 (106.3) | 94.4 (109.0) | 79.6, 112.0 | 0.504 |
| Adrenaline, pg/mL | ||||||
| Valsartan (n = 54) | 91.4 (231.6) | 53.4 (50.7) | 84.4 (108.2) | |||
| Placebo (n = 64) | 60.2 (42.9) | 63.6 (59.3) | 97.3 (107.5) | 86.7 (110.7) | 70.9, 106.0 | 0.161 |
| PRA, ng/mL/h | ||||||
| Valsartan (n = 61) | 4.9 (10.6) | 7.8 (10.9) | 181.8 (122.5) | |||
| Placebo | 4.0 (7.7) (n = 71) | 3.8 (7.6) (n = 72) | 93.1 (121.0) (n = 71) | 195.4 (130.5) | 115.4, 331.0 | 0.013 |
| Aldosterone, pg/mL | ||||||
| Valsartan | 170.2 (101.0) (n = 57) | 134.9 (88.7) (n = 59) | 78.9 (107.3) (n = 57) | |||
| Placebo | 174.6 (113.3) (n = 68) | 169.9 (103.6) (n = 70) | 99.2 (106.7) (n = 68) | 79.5 (109.7) | 66.2, 95.6 | 0.015 |
| PIIINP, µg/mL | ||||||
| Valsartan (n = 60) | 3.3 (1.1) | 3.3 (0.9) | 98.3 (103.0) | |||
| Placebo (n = 72) | 3.5 (1.1) | 3.6 (1.1) | 104.4 (102.7) | 94.1 (103.9) | 87.2, 101.5 | 0.114 |
BNP, brain natriuretic peptide; PIIINP, procollagen type III amino-terminal peptide; PRA, plasma renin activity; SD, standard deviation; SEM, standard error of the mean.
aValsartan relative to placebo.